Delving into the Latest Updates on Zhejiang Boxiao Biopharmaceutical Co., Ltd. with Synapse

Overview

Tags

Congenital Disorders

Immune System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Monoclonal antibody	1

Top 5 Target	Count

D1 receptor(Dopamine D1 receptor)	1
IGF-1R(Insulin-like growth factor I receptor)	1

主要目的：测定在健康女性受试者中马来酸甲麦角新碱注射液单次静脉注射和肌肉注射给药后不同时间的药物浓度，评估其药代动力学特征。次要目的：分别评价在健康女性受试者中马来酸甲麦角新碱注射液单次静脉注射和肌肉注射给药的安全性和耐受性。

[Translation]

Primary objective: To determine the drug concentrations at different times after a single intravenous and intramuscular injection of methylergonovine maleate injection in healthy female subjects and to evaluate its pharmacokinetic characteristics. Secondary objective: To evaluate the safety and tolerability of a single intravenous and intramuscular injection of methylergonovine maleate injection in healthy female subjects.

Start Date16 May 2024

Sponsor / Collaborator

Zhejiang Boxiao Biopharmaceutical Co., Ltd.

CTR20241201 / RecruitingPhase 1

一项评估静脉输注HSP638DP在健康受试者中的安全性、耐受性、药代动力学及药效学特征的随机、双盲、平行、安慰剂对照、单次剂量递增的I期临床研究

[Translation] A randomized, double-blind, parallel, placebo-controlled, single-dose escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous infusion of HSP638DP in healthy subjects

主要目的：评估健康受试者单次静脉输注HSP638DP后的安全性与耐受性，为后期临床试验给药方案提供安全的剂量范围；次要目的：评价健康受试者单次静脉输注HSP638DP的药代动力学特征，评价健康受试者单次静脉输注HSP638DP的免疫原性；探索性目的：探索健康受试者静脉输注HSP638DP后的药效学指标。

[Translation]

Primary purpose: To evaluate the safety and tolerability of HSP638DP after a single intravenous infusion in healthy subjects, and to provide a safe dosage range for the dosing regimen of later clinical trials; Secondary purpose: To evaluate the pharmacokinetic characteristics of HSP638DP after a single intravenous infusion in healthy subjects, and to evaluate the immunogenicity of HSP638DP after a single intravenous infusion in healthy subjects; Exploratory purpose: To explore the pharmacodynamic indicators of HSP638DP after intravenous infusion in healthy subjects.

Start Date08 Apr 2024

Sponsor / Collaborator

Zhejiang Boxiao Biopharmaceutical Co., Ltd.

100 Clinical Results associated with Zhejiang Boxiao Biopharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Boxiao Biopharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Boxiao Biopharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Boxiao Biopharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

Login to view more data